Recently we reported financial results for the third quarter ended September 30, 2026 and summarized recent business highlights.
Read our full press release here: revivapharma.com/reviva-repo…
$RVPH
1
300
Reviva CEO Laxminarayan Bhat, Ph.D., presented at the Lytham Partners Fall 2026 Investor Conference, highlighting brilaroxazine’s Phase 3 and long-term data, proposed formulation, and path toward an NDA submission.
Watch the full presentation here youtube.com/watch?v=IIaTT66n…
$RVPH
191
Laxminarayan Bhat, PhD., Founder, President and CEO, will present and participate in a webcast presentation at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.
View press release: revivapharma.com/reviva-to-p…
$RVPH
295
Recently we reported financial results for the second quarter ended June 30, 2026 and summarized recent business highlights.
Read our full press release here: revivapharma.com/reviva-repo…
$RVPH
3
489
President & CEO Laxminarayan Bhat, Ph.D. will present at the Life Sciences Investor Forum on June 24 at 1:30PM ET.
View press release for details: revivapharma.com/reviva-phar…
$RVPH
1
367
Reviva Pharmaceuticals Founder, President & CEO, Laxminarayan Bhat, Ph.D., will be attending #BIO2026 June 22-25.
Looking forward to connecting with leaders across the biotech and biopharma industries.
Learn more: convention.bio.org/about-bio
$RVPH
1
529
Founder & CEO Laxminarayan Bhat, Ph.D. recently participated in a company webcast presentation at the @LythamIR Spring 2026 Investor Conference.
Watch the replay here: youtu.be/GWSvrgl0dzc?si=mqP6…
$RVPH
1
573
Reviva Pharmaceuticals retweeted
See our extended interview with @RevivaPharma's CEO Dr Bhat. #brilaroxazine #schizophrenia
$RVPH
youtu.be/euVZhOVrtdg
President & CEO Laxminarayan Bhat, Ph.D. will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase on Wednesday, May 20, 2026 at 2:40 PM ET
View press release for details: revivapharma.com/reviva-to-p…
$RVPH
2
493
Today we reported financial results for the first quarter ended March 31, 2026 and summarized recent business highlights including.
Read our full press release here: revivapharma.com/reviva-repo…
$RVPH
473
Reviva Pharmaceuticals retweeted
We speak with @RevivaPharma's CEO Dr. Laxminarayan Bhat about recent M&A in the CNS space.
$RVPH
#schizophrenia #biopharma #biotech
youtube.com/shorts/L_3faJiyT…
Reviva Pharmaceuticals retweeted
Replying to @RevivaPharma
@RevivaPharma CEO Dr Laxminarayan Bhat talks with us about brilaroxazine's #ADHD indication & how it relates to other behavioral disorders.
$RVPH
#schizophrenia #biopharma #biotech
youtube.com/shorts/0JkwB-YKt…
Reviva Pharmaceuticals retweeted
Replying to @RevivaPharma
@RevivaPharma CEO Dr Laxminarayan Bhat discusses the vocal biomarker that was developed in the RECOVER trial.
$RVPH
#schizophrenia #biopharma #biotech
youtu.be/vngRvpKDGZ8
AGP’s James Molloy joins Reviva CEO Laxminarayan Bhat, Ph.D. to discuss the Phase 3 RECOVER-2 trial in schizophrenia and what it means for brilaroxazine across multiple neuropsychiatric indications.
Watch here: vimeo.com/1188097611/1b941f4…
$RVPH
1
1
808
Reviva Pharmaceuticals retweeted
Replying to @RevivaPharma
@RevivaPharma CEO Dr Laxminarayan Bhat describes the trial design for RECOVER 2 which will evaluate schizophrenia patients with a four week regimen of brilaroxazine at 30 and 50 mg.
$RVPH
#schizophrenia #biopharma #biotech
youtube.com/shorts/8SoS4jYPT…
Reviva Pharmaceuticals retweeted
Replying to @RevivaPharma
@RevivaPharma CEO Dr Laxminarayan Bhat looks ahead to other indications for brilaroxazine and what their market potential may be.
$RVPH
#schizophrenia #biopharma #biotech
youtube.com/shorts/IE5ZxiLfm…
Reviva Pharmaceuticals retweeted
Replying to @RevivaPharma
@RevivaPharma CEO Dr Laxminarayan Bhat explains why most trials evaluating new atypical antipsychotics begin with schizophrenia and then pursue other indications in major depressive disorder and bipolar disorder later.
#schizophrenia #biopharma #biotech
youtube.com/shorts/-ugVYnRt4…
Reviva Pharmaceuticals retweeted
Replying to @RevivaPharma
@RevivaPharma expects to use a reformulation of brilaroxazine in its RECOVER 2 trial. CEO Dr Laxminarayan Bhat identifies the three changes that will be made to extend and strengthen the patent.
#schizophrenia #biopharma #biotech
youtube.com/shorts/-m8rPNmfY…





